We demonstrate that combining asciminib with ATP site TKIs enhances target inhibition and suppression of resistant outgrowth in Ph+ clinical isolates and cell lines. Inclusion of asciminib restores ponatinib's effectiveness against currently untreatable compound mutants at clinically achievable concentrations. Our findings support combining asciminib with ponatinib as a treatment strategy for this molecularly defined group of patients.
https://www.sciencedirect.com/science/article/abs/pii/S1535610819303721?via%%203Dihub
Article type:
Original publication date:
Thursday, October 3, 2019